The ACAD9 antibody is a crucial tool for studying acyl-CoA dehydrogenase family member 9 (ACAD9), a mitochondrial enzyme essential for fatty acid β-oxidation and the assembly of mitochondrial respiratory chain Complex I. ACAD9 catalyzes the dehydrogenation of long-chain acyl-CoAs, linking lipid metabolism to cellular energy production. Mutations in the ACAD9 gene are associated with mitochondrial disorders, particularly early-onset hypertrophic cardiomyopathy, encephalopathy, and Complex I deficiency.
ACAD9 antibodies enable the detection and quantification of ACAD9 protein levels in tissues and cells, aiding research into its dual metabolic and structural roles. These antibodies are widely used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to investigate ACAD9 expression patterns, subcellular localization, and interactions with Complex I subunits. They are also vital for diagnosing ACAD9-related disorders and evaluating therapeutic interventions in preclinical models.
Available as monoclonal or polyclonal variants, ACAD9 antibodies require rigorous validation using knockout controls or siRNA-mediated silencing to ensure specificity. Their application extends to studying metabolic adaptations in conditions like obesity, diabetes, and cancer, where altered fatty acid oxidation impacts disease progression. By elucidating ACAD9's role in mitochondrial health, these antibodies contribute to advancing our understanding of metabolic diseases and genetic mitochondrial dysfunction.